- Home
- ODD vs APGE Comparison
ODD vs APGE Comparison
Compare ODD & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- APGE
- Stock Information
- Founded
- ODD 2018
- APGE 2022
- Country
- ODD Israel
- APGE United States
- Employees
- ODD N/A
- APGE N/A
- Industry
- ODD
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODD
- APGE Health Care
- Exchange
- ODD Nasdaq
- APGE Nasdaq
- Market Cap
- ODD 2.3B
- APGE 2.1B
- IPO Year
- ODD 2023
- APGE 2023
- Fundamental
- Price
- ODD $71.00
- APGE $37.29
- Analyst Decision
- ODD Buy
- APGE Strong Buy
- Analyst Count
- ODD 8
- APGE 4
- Target Price
- ODD $54.63
- APGE $91.33
- AVG Volume (30 Days)
- ODD 1.1M
- APGE 545.3K
- Earning Date
- ODD 04-29-2025
- APGE 05-20-2025
- Dividend Yield
- ODD N/A
- APGE N/A
- EPS Growth
- ODD 45.36
- APGE N/A
- EPS
- ODD 1.74
- APGE N/A
- Revenue
- ODD $703,488,000.00
- APGE N/A
- Revenue This Year
- ODD $22.39
- APGE N/A
- Revenue Next Year
- ODD $20.09
- APGE $743.14
- P/E Ratio
- ODD $40.82
- APGE N/A
- Revenue Growth
- ODD 26.83
- APGE N/A
- 52 Week Low
- ODD $32.71
- APGE $26.20
- 52 Week High
- ODD $69.96
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- ODD 84.66
- APGE 52.37
- Support Level
- ODD $39.55
- APGE $34.38
- Resistance Level
- ODD $43.14
- APGE $41.05
- Average True Range (ATR)
- ODD 3.73
- APGE 2.23
- MACD
- ODD 2.35
- APGE 0.10
- Stochastic Oscillator
- ODD 99.78
- APGE 51.48
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.